David Rakel MD, FAAFP
Professor and Chair, Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, WisconsinDr. David Rakel is Professor and Chair of the Department of Family Medicine and Community Health at the University of Wisconsin. During his time at UW–Madison, he founded the Integrative Medicine Program (now known as the Integrative Health Program) and received the Gold Foundation’s Leonard Tow Humanism in Medicine Award, the school’s highest honor for excellence and compassion in care. His team worked with more than 50 clinical systems within the Veterans Health Administration to implement changes to make care more personalized, proactive, and patient-driven.
After residency training in family medicine in Colorado, Dr. Rakel worked in private practice in rural Idaho. His burgeoning interest in the relationships across health, the human experience, and the environment led to a fellowship in integrative medicine at the University of Arizona.
An author of both academic and popular writings, Dr. Rakel says one of his missions is to communicate medical information in a way that is accessible to people of all backgrounds.
Recent Contributions to PracticeUpdate:
- Integration of a Fasting-Mimicking Diet Programme in Primary Care for Type 2 Diabetes Reduces the Need for Medication and Improves Glycaemic Control
- Xylitol Is Prothrombotic and Associated With CV Risk
- Association of Mediterranean Diet Adherence With Risk of All-Cause Mortality in Women
- The Impact of Primary Care Clinic and Family Physician Continuity on Patient Health Outcomes
- The 2024 Guideline for the Management of Lower Extremity Peripheral Artery Disease
- Surveillance of the Liver in Type 2 Diabetes
- Associations of Testosterone and Related Hormones With All-Cause and Cardiovascular Mortality and Incident Cardiovascular Disease in Men
- Association of Consumption of Olive Oil and Diet Quality With the Risk of Dementia-Related Death
- Effect of Combination Treatment With GLP-1 Receptor Agonists and SGLT-2 Inhibitors on Incidence of Cardiovascular and Serious Renal Events
- Newer Pharmacologic Treatments in Adults With Type 2 Diabetes